Canandaigua National Bank & Trust Co. Has $16.87 Million Stock Position in Johnson & Johnson $JNJ

Canandaigua National Bank & Trust Co. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 90,977 shares of the company’s stock after selling 4,709 shares during the period. Johnson & Johnson makes up 1.5% of Canandaigua National Bank & Trust Co.’s holdings, making the stock its 12th biggest holding. Canandaigua National Bank & Trust Co.’s holdings in Johnson & Johnson were worth $16,869,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson in the second quarter valued at approximately $27,000. Semmax Financial Advisors Inc. raised its position in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares during the last quarter. GFG Capital LLC bought a new position in Johnson & Johnson during the 2nd quarter valued at $35,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter worth $48,000. Finally, Vermillion & White Wealth Management Group LLC raised its holdings in shares of Johnson & Johnson by 66.4% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after purchasing an additional 150 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several analyst reports. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target on the stock in a report on Monday, October 20th. Argus set a $210.00 target price on Johnson & Johnson in a research note on Wednesday, October 15th. UBS Group increased their price target on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research report on Tuesday, October 14th. Bank of America lifted their price target on Johnson & Johnson from $204.00 to $220.00 and gave the stock a “neutral” rating in a report on Monday. Finally, JPMorgan Chase & Co. upped their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Four analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $208.85.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $210.50 on Thursday. The business’s 50 day simple moving average is $197.44 and its 200 day simple moving average is $178.46. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $215.18. The company has a market cap of $507.14 billion, a price-to-earnings ratio of 20.32, a PEG ratio of 2.27 and a beta of 0.36. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.